Navigation Links
ESBATech's Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
Date:4/24/2008

ESBA105 Penetrates all Segments of the Eye via Topical Eye Drops

ZURICH, Switzerland, April 24 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of Phase I clinical development of the company's lead product development candidate, ESBA105, in ophthalmology. This Phase I study is designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. The study is being conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNFa. It is being developed initially for ophthalmic indications.

In previously reported in vivo, preclinical studies, ESBA105 achieved high therapeutic concentrations in all ocular tissues, when delivered topically via eye drops. Therapeutic concentrations of ESBA105 were observed throughout the anterior (front) and the posterior (back) segments of the eye, the latter including the vitreous humor, retina and choroid.

Peter Lichtlen, M.D., Ph.D., Head of Clinical Development at ESBATech AG, commented, "ESBA105 shows an entirely novel and unique intraocular distribution pattern upon topical administration to the eye. Therapeutic levels are reached in both the aqueous and vitreous humor after only a couple of hours following initiation of treatment. Our in vivo, preclinical studies have shown that ESBA105 has a prolonged half-life of 25 hours in the vitreous. Thus, the vitreous acts as a natural depot compartment for ESBA105, allowing for highly attractive maintenance dosing regimens. TNFa is a rapidly emerging target in ophthalmology and ESBA105 has the potential to be a significant advancement in anti-inflammatory ophthalmic medicine."

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, added, "This is a major corporate milestone for ESBATech. After having developed a repeatable technol
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
5. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
6. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
7. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
8. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
9. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
10. Celltrion and CSL Announce Collaboration to Develop and Manufacture Monoclonal Antibody
11. Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014  Sage Analytics ( www.sageanalytics.com ), ... for the testing of marijuana potency and moisture ... Luminary™ Profiler, the industry,s first product suite capable ... cost-effective, portable unit. Designed from the ... the cannabis industry, the Luminary™ Profiler utilizes specially ...
(Date:12/19/2014)... , Dec. 18, 2014 Baptist Health Lexington is ... to receive full Atrial Fibrillation with Electrophysiology Services (EPS) ... Atrial fibrillation is the most common cardiac arrhythmia ... some cases can lead to stroke and possible death. More ... have atrial fibrillation and the numbers are rapidly ...
(Date:12/19/2014)... membrane market has witnessed robust development with the growth pace ... later starter. In 2012, the size of China ... the proportion worldwide soaring to 16.3%. It is projected that ... its growth rate by around 20% in the upcoming years ... RMB25 billion. An integrated membrane industrial system has ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... 2011 Nephros, Inc. (OTC Bulletin Board: NEPHD ... for therapeutic applications, infection control, and water purification, announced today ... December 31, 2010. 2010 Highlights ... prior year period Increased gross margin by 22% to ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... a proposal to the Board of Directors of Cephalon, ... for $73.00 per share in cash.  The proposal, valued ... 29% over Cephalon,s 30-day trading average.  Valeant announced its ...
Cached Medicine Technology:Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 2Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 3Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 4Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 5Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 6Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 7Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 8Nephros Reports 2010 Fourth Quarter and Full Year Financial Results 9Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 2Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 3Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 4Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 5Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 6Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 7Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 8Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 9Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 10Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 11Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash 12
(Date:12/19/2014)... 19, 2014 Energy Textiles is ... now available. Celliant, the world’s leading responsive textile, ... pillowcases. , There are a number of benefits ... increased oxygenation and balanced body temperature; which can ... pain relief; enhanced athletic performance; and overall wellness. ...
(Date:12/19/2014)... 19, 2014 Silver Dollar City ... record -- for the first time ever, Silver Dollar City ... Guinness World Records 2015, listing the park’s wood coaster Outlaw ... In additional awards announced this week, Silver Dollar City is ... in the US,” USA Today’s 10Best awards for “Best Public ...
(Date:12/19/2014)... December 19, 2014 Eufaula, Oklahoma, located ... Lake Eufaula, the state’s largest lake with more than ... is home to a little more than 3,000 residents, ... on Saturday, the 6th of December. , Featuring Santa, ... through downtown Eufaula on Main Street. Narconon Arrowhead’s ...
(Date:12/19/2014)... An evening dress is perfect for any occasion and ... distinguished dresses retailer, has unveiled its new selection of evening ... great shopping platform. Customers can view more at ... has been accepted and praised by customers for many years. ... for clients. In order to expand its market share, the ...
(Date:12/19/2014)... The print component of Vision and Hearing is ... Toronto Star, with a circulation of approximately 230,433 copies ... is distributed nationally through a vast social media strategy ... partner outlets. To explore the digital version of the ... an exclusive interview with Mark DeMontis , sharing ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2
... investigators Lewis C. Cantley, PhD, and Cornelius P. Terhorst, PhD, ... American Association for the Advancement of Science. They are ... distinguished efforts to advance science, and will be honored during ... BIDMC,s Division of Signal Transduction and Director of the BIDMC ...
... This release is available in German . ... of recovery depending on disease stage. Experts hope that the ... is more helpful in the choice of the right treatment ... for Quality and Efficiency in Health Care (IQWiG) has now ...
... 2011 HIV-positive head and neck cancer patients respond ... rates as non-HIV-positive patients, despite prior reports to the ... of the International Journal of Radiation OncologyBiologyPhysics , ... Oncology (ASTRO). , Patients with HIV have a significantly ...
... The combined results of a genetic blood test and ... of healthy older adults, many of whom were destined ... John Woodard, Ph.D., associate ... and Sciences and Institute of Gerontology at Wayne State ...
... (Jan. 19, 2011) A new program designed to create ... Colorado has received a $3.9 million grant from the Colorado ... four-year program housed in the Department of Family Medicine at ... brings together local and national leaders from the mental health, ...
... Dotinga HealthDay Reporter , TUESDAY, Jan. 18 (HealthDay ... that aims to reveal the presence of Alzheimer,s disease, potentially ... early stages. Another study finds that blood tests could indicate ... there,s a catch: Alzheimer,s disease is not curable, and existing ...
Cached Medicine News:Health News:Malignant brain tumors: Benefit of PET and PET/CT in the detection of recurrences is not assessable 2Health News:HIV-positive head and neck cancer patients benefit from radiation therapy 2Health News:Wayne State University study predicts risk of memory loss in healthy, older adults 2Health News:New program targeting whole-person health care gets major grant 2Health News:Progress Reported in Predicting Alzheimer's 2